Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
RESEARCH TOOLSreports
Holding VVOS?
Track your performance easily
VVOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.91 - $48.79
Previous Close$2.81
Volume68.39K
Average Volume (3M)62.50K
Market Cap
$9.54M
Enterprise Value$8.83M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$1.88M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Aug 13, 2024EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.32
Shares Outstanding3,227,270
10 Day Avg. Volume45,841
30 Day Avg. Volume62,502
Standard Deviation1.12
R-Squared0.12
Alpha0.00281
Financial Highlights & Ratios
Price to Book (P/B)223.00
Price to Sales (P/S)0.45
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit0.88
Enterprise Value/Ebitda2.72
Forecast
1Y Price Target
$6.40Price Target Upside131.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Vivos Therapeutics News
PremiumCompany Announcements
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones
Bulls Say, Bears Say
Bulls Say
Cost ControlOperating expenses in Q1 were down 22% year-over-year, reflecting the company's focus on cost control.
Revenue GrowthThe company's FDA approval for severe sleep apnea treatment and strategic moves to open new distribution channels showcase potential for future revenue growth.
Strategic PartnershipsNew monetization channel for Vivos includes distribution partnerships and a new partnership initiative to gain direct access to OSA patients.
Bears Say
EarningsAnalyst lowers FY24 EPS estimates due to slightly lower revenue expectations and slightly higher cost estimates.
Financial PerformanceQ4 revenue was significantly below analyst expectations, signaling a potential concern for the company's financial performance.
RevenueRevenue was $3.4 million, down 11% year-over-year.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $1.91 and its highest was $48.79 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Currently, no data Available
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Aug 13, 2024 which is 100 days ago.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on May 14, 2024. The company reported -$1.63 earnings per share for the quarter, missing the consensus estimate of -$1.175 by -$0.455.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -$1.05.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 3,396,768 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$1.63 in its last earnings report, missing expectations of -$1.175. Following the earnings report the stock price went down -12.45%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
---
Vivos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.40 (131.88% Upside)
$6.40 (131.88% Upside)
Blogger Sentiment
Bullish
VVOS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.76%
12-Months-Change
Fundamentals
Return on Equity
-413.02%
Trailing 12-Months
Asset Growth
-30.97%
Trailing 12-Months
Company Description
Vivos Therapeutics
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment of sleep-disordered breathing including mild-to-moderate obstructive sleep apnea resulting from underdeveloped upper and lower jaws.
---
VVOS Earnings Call
Q1 2024
0:00 / 0:00
---
VVOS Stock 12 Month Forecast
Average Price Target
$6.40
▲(131.88% Upside)
Technical Analysis
Best Analysts Covering VVOS
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-31.36%
reiterated a buy rating 6 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -31.36% per trade.
---